

**• Name:**

Jeong-Ok Lee

**• Affiliation/Current Position:**

Seoul National University Bundang Hospital/ Professor

**• Country:**

South Korea

**• ICKSH2022 Presentation Title:**

EHA-KSH Joint Symposium

**• Educational Background:**

M.D. 2003 Yeungnam University College of Medicine, Daegu, Korea

M.Sc. 2009 Molecular oncology, Department of Medicine, Graduate School, Seoul National University College of Medicine, Seoul, Korea

Ph.D. 2017 Molecular oncology, Department of Medicine, Graduate School, Seoul National University College of Medicine, Seoul, Korea

**• Professional Experiences:**

2004-2005 Internship, Seoul National University Hospital, Seoul, Korea

2005-2009 Resident, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

2009-2010 Clinical Fellow, Division of Hemato-oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

2010-2012 Instructor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea

2012-2016 Assistant professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea

2018 Visiting Scholar, Leukemia service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

2016-2021 Associate professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea

2021- Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea

**• Professional Organizations**

Member of the Korean Society of Hematology

Member of the Korean Society of Blood and Marrow Transplantation

Member of the American Society of Hematology

**• Main Scientific Publications :**

Lee JY, Paik JH, Suh KJ, Kim JW, Kim SH, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS, Lee JO. R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience. *Blood Res* 2021 Nov 22 [online ahead of print]

Byun JM, Shin DY, Koh Y, Hong J, Kim I, Yoon SS, Lee JY, Bang SM, Lee JO. Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission? *Ther Adv Hematol* 2021 Apr 20

Lee JY, Kang M, Suh KJ, Kim JW, Kim SH, Kim JW, Kim YJ, Song KH, Kim ES, Kim HB, Lee KW, Kim JH, Bang SM, Lee JS, Lee JO. Pneumocystis jirovecii pneumonia in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. *Mycoses* 2021;64:60-65

Byun JM, Lee JO, Suh KJ, Lee J, Shin DY, Koh Y, Hong J, Bang SM, Kim I, Yoon SS. The role of anthracyclines in acute myeloid leukemia consolidation. *Anticancer Res* 2020;40:357-366

Choi M, Lee JO, Jung J, Lee JY, Lee E, Lee H, Bang SM, Eom HS, Lee JS. Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma. *Acta Haematol* 2019;141(3):176-186

Lee JO, Lee JY, Chun EJ, Choi SI, Kim JW, Kim SH, Kim YJ, Lee KW, Kim JH, Lee JS, Bang SM. Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study. *Support Care Cance*. 2019;27(7): 2507-2515

Byun JM, Kim KH, Kim M, Kim TM, Jeon YK, Park JH, Paik JH, Lee JM, Lee HY, Lee JS, Heo DS, Lee JO. Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. *Leuk Lymphoma*. 2017;58(11): 2624-2632

Suh KJ, Lee JY, Shin DY, Koh Y, Bang SM, Yoon SS, Park S, Kim I, Lee JO. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. *Int J Hematol*. 2017;106(2): 229-239